Switching between infliximab biosimilar SB2 and the reference product did not affect clinical disease activity or safety in IBD patients. No significant changes were observed in clinical outcomes, ...
Dec. 22, 2004 — The U.S. Food and Drug Administration (FDA) and Centocor have warned healthcare professionals via letter regarding risks of hepatotoxicity and pneumonia associated with the use of ...
Original Medicare covers most medically necessary treatments for rheumatoid arthritis (RA), including biologics like adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Inflectra), and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback